- Home
- HCWB vs RNXT Comparison
HCWB vs RNXT Comparison
Compare HCWB & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- RNXT
- Stock Information
- Founded
- HCWB 2018
- RNXT 2012
- Country
- HCWB United States
- RNXT United States
- Employees
- HCWB N/A
- RNXT N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- HCWB Health Care
- RNXT Health Care
- Exchange
- HCWB Nasdaq
- RNXT Nasdaq
- Market Cap
- HCWB 26.6M
- RNXT 21.6M
- IPO Year
- HCWB 2021
- RNXT 2021
- Fundamental
- Price
- HCWB $0.31
- RNXT $1.08
- Analyst Decision
- HCWB
- RNXT Strong Buy
- Analyst Count
- HCWB 0
- RNXT 3
- Target Price
- HCWB N/A
- RNXT $6.13
- AVG Volume (30 Days)
- HCWB 96.6K
- RNXT 29.1K
- Earning Date
- HCWB 11-19-2024
- RNXT 11-13-2024
- Dividend Yield
- HCWB N/A
- RNXT N/A
- EPS Growth
- HCWB N/A
- RNXT N/A
- EPS
- HCWB N/A
- RNXT N/A
- Revenue
- HCWB $3,922,670.00
- RNXT N/A
- Revenue This Year
- HCWB N/A
- RNXT N/A
- Revenue Next Year
- HCWB N/A
- RNXT N/A
- P/E Ratio
- HCWB N/A
- RNXT N/A
- Revenue Growth
- HCWB 2.82
- RNXT N/A
- 52 Week Low
- HCWB $0.28
- RNXT $0.53
- 52 Week High
- HCWB $1.93
- RNXT $2.35
- Technical
- Relative Strength Index (RSI)
- HCWB 26.31
- RNXT 57.50
- Support Level
- HCWB $0.42
- RNXT $1.04
- Resistance Level
- HCWB $0.50
- RNXT $1.05
- Average True Range (ATR)
- HCWB 0.04
- RNXT 0.07
- MACD
- HCWB -0.01
- RNXT 0.01
- Stochastic Oscillator
- HCWB 4.39
- RNXT 71.43
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.